Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$884.48 USD

884.48
2,454,077

-1.46 (-0.16%)

Updated Oct 1, 2024 04:00 PM ET

Pre-Market: $880.27 -4.21 (-0.48%) 9:24 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Lilly Gets Favorable Ruling in Alimta Patent Lawsuit in UK

by Zacks Equity Research

Eli Lilly and Company (LLY) announced that it has received favorable ruling from the UK Supreme Court in a patent lawsuit against generic drugmaker, Actavis related to its key cancer drug, Alimta (pemetrexed disodium).

    Array (ARRY) Submits NDA for Melanoma Combination Therapy

    by Zacks Equity Research

    Array BioPharma (ARRY) announced that it has submitted two new drug applications (NDAs) to FDA, seeking approval for the combination of binimetinib and encorafenib to treat patients with BRAF-mutant advanced, unresectable or metastatic melanoma.

      Sanofi Versus AstraZeneca: Large Cap Pharma Stock Faceoff

      by Zacks Equity Research

      Both stocks carry a Zacks Rank #2 (Buy).

        Merck Falls as FDA Puts Hold on 3 Keytruda Myeloma Studies

        by Zacks Equity Research

        Merck & Co., Inc. (MRK) shares were down more than 1% in after-hours trading on Wednesday after the company announced that the FDA has placed a clinical hold on three combination studies of Keytruda in multiple myeloma, a form of blood cancer.

          Incyte & Lilly's Olumiant Gets Marketing Approval in Japan

          by Zacks Equity Research

          Incyte Corporation (INCY) and partner Eli Lilly and Company (LLY) announced that arthritis drug Olumiant got approval in Japan.

            Alkermes Presents Phase III Data on Schizophrenia Candidate

            by Zacks Equity Research

            Alkermes plc (ALKS) announced positive preliminary top-line results from a phase III study, ENLIGHTEN-1, evaluating its schizophrenia candidate, ALKS 3831.

              Novartis Gets EC Nod for Lung Cancer Drug's Label Expansion

              by Zacks Equity Research

              Novartis AG (NVS) announced that the European Commission has approved a label expansion of lung cancer drug drug Zykadia.

                Alder's Shares Dip Despite Positive Migraine Trial Results

                by Zacks Equity Research

                Alder Biopharmaceuticals, Inc.'s (ALDR) shares plummeted almost 28% despite the announcement of positive top line results from phase III study, evaluating its lead pipeline candidate eptinezumab for prevention of frequent episodic migraine.

                  Merck's CETP Inhibitor Reduces CV Risk in Phase III Study

                  by Zacks Equity Research

                  Merck & Co., Inc. (MRK) announced that a large late-stage cardiovascular outcomes study (REVEAL) evaluating anacetrapib, a cholesterol-lowering medicine, met the primary endpoint by reducing cardiovascular (CV) risk.

                    Novartis Cardiovascular Drug Positive, NSCLC Drug Approved

                    by Zacks Equity Research

                    Shares of Novartis AG (NVS) were up after the company announced positive top-line results from the global phase III study, CANTOSon cardiovascular drug.

                      Why You Should Add Novo Nordisk Stock to Your Portfolio

                      by Zacks Equity Research

                      Novo Nordisk (NVO) is healthcare company and a with leadership in the global diabetes market. It looks like a great stock to buy now.

                        Merck's Keytruda on a Roll: Can it Retain the Momentum?

                        by Zacks Equity Research

                        As demand for immuno-oncology drugs and their combinations rises, Merck & Co., Inc.'s (MRK) anti-PD-1 therapy, Keytruda, is being touted as a significant top-line driver for this Kenilworth, NJ based pharma giant.

                          Novo Nordisk's Victoza Gets FDA Panel Nod for Label Expansion

                          by Zacks Equity Research

                          Novo Nordisk A/S (NVO) announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 17-2 in favor of Victoza that the drug provides substantial evidence of cardiovascular risk reduction in patients with type II diabetes.

                            5 Reasons Why You Should Invest in AstraZeneca (AZN) in 2017

                            by Zacks Equity Research

                            London-based pharma giant, AstraZeneca plc (AZN) has a strong product portfolio and is one of the key players in the global cardiovascular market.

                              Why Is ImmunoGen (IMGN) Stock Up 131% This Year?

                              by Zacks Equity Research

                              Shares of ImmunoGen, Inc. (IMGN) are massively up 130.9% this year so far, outperforming the the Zacks classified Medical-Drugs industry's registered 3.6% increase during this period.

                                Pfizer & Lilly Get Fast Track Designation for Pain Candidate

                                by Zacks Equity Research

                                Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) announced that the FDA has granted fast track designation to their pipeline candidate, tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP).

                                  Company News for June 14, 2017

                                  by Zacks Equity Research

                                  Companies in the News are: LLY,PFE,CAKE,JW.A,CVCO

                                    J&J's Invokana Lowers Heart Issues, Raises Amputation Risk

                                    by Zacks Equity Research

                                    Johnson & Johnson (JNJ) announced data from a large CANVAS outcomes program, which demonstrated that its type II diabetes drug Invokana (canagliflozin) was successful in reducing the risks of heart attacks and strokes.

                                      Merck Stalls Enrolment in Two Myeloma Studies of Keytruda

                                      by Zacks Equity Research

                                      Merck & Co., Inc. (MRK) announced that it is pausing two late-stage studies evaluating its anti-PD-1 therapy, Keytruda, as a combination therapy for the treatment of multiple melanoma, a form of blood cancer.

                                        Lilly Plans New Outcomes Study to Expand Jardiance Label

                                        by Zacks Equity Research

                                        Eli Lilly and Company (LLY) along with partner Boehringer Ingelheim are planning to conduct a new outcomes study to evaluate the type II diabetes drug Jardiance (empagliflozin) for treatment of patients with chronic kidney disease.

                                          Novartis Presents Positive Data on CAR-T Cell Therapy Drug

                                          by Zacks Equity Research

                                          Novartis AG (NVS) announced data from an interim analysis from a phase II study on lymphoma candidate.

                                            Alkermes Commences Phase III Study for Schizophrenia Drug

                                            by Zacks Equity Research

                                            Alkermes plc (ALKS) announced that it initiated a phase III study, ENLIGHTEN-Early on experimental candidate, ALKS 3831.

                                              Merck's Diabetes Drug Meets Primary Endpoint in Key Studies

                                              by Zacks Equity Research

                                              Merck & Co., Inc. (MRK) and partner Pfizer Inc. (PFE) announced that its pipeline candidate, ertugliflozin, met primary endpoints in two late stage studies evaluating ertugliflozin in adults with Type 2 diabetes.

                                                AbbVie (ABBV) Announced Positive Phase III RA Candidate Data

                                                by Zacks Equity Research

                                                AbbVie Inc. (ABBV) announced positive top-line results from a phase III study on rheumatoid arthritis candidate, upadacitinib (ABT-494).

                                                  Teva Migraine Candidate Succeeds in Second Phase III Study

                                                  by Zacks Equity Research

                                                  Teva announced that its experimental migraine prevention candidate, fremanezumab, met all the primary and secondary endpoints in a second late-stage study.